• Good news for newly diagosed with EGFR mutation

    Asked by LiveWithCancer on Sunday, April 22, 2018

    Good news for newly diagosed with EGFR mutation

    FDA Approves Osimertinib for First-Line Treatment of NSCLC
    The FDA has approved osimertinib (Tagrisso) for frontline use in patients with non–small cell lung cancer (NSCLC) who have EGFR-mutated tumors (exon 19 deletions or exon 21 L858R substitution mutations).

    The approval is based on the phase III FLAURA study, in which frontline osimertinib reduced the risk of progression or death by 54% versus standard tyrosine kinase inhibitor (TKI) therapy—erlotinib (Tarceva) or gefitinib (Iressa). In the double-blind study, the median progression-free survival (PFS) was 10.2 months (95% CI, 9.6-11.1) for standard therapy and 18.9 months (95% CI, 15.2-21.4) with osimertinib (HR, 0.46; 95% CI, 0.37-0.57; P <.0001).


    2 Answers from the Community

    • GregP_WN's Avatar

      More great news about the newest form of treatments. I hope they are able to move faster in the future to bring these types of treatments to the patients.

      11 months ago
    • SandiA's Avatar

      We will always take good news. All new promising treatments!

      11 months ago

    Help the community by answering this question:

    Create an account to post your answer Already have an account? Sign in!

    By using WhatNext, you agree to our User Agreement, and Privacy Policy

    Read and answer more adenocarcinoma, lung cancer questions.  Also, don't forget to check out our Adenocarcinoma, Lung Cancer page.